<DOC>
	<DOCNO>NCT00567996</DOCNO>
	<brief_summary>This study evaluate safety efficacy 26 week treatment indacaterol , placebo salmeterol patient chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>Efficacy Safety Indacaterol Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Using Salmeterol Active Control</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Clinical diagnosis moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) per Global Initiative Chronic Obstructive Lung Disease ( GOLD ) 2006 Guidelines ( mandatory ) include : Smoking history least 20 pack year Postbronchodilator Forced Expiratory Volume 1 second ( FEV1 ) &lt; 80 % predict &gt; or= 30 % predict normal value Postbronchodilator FEV1/FVC &lt; 70 % ( `` Post '' define within 30 minute inhalation 400 Âµg salbutamol ) Pregnant nursing ( lactate ) woman woman childbearing potential UNLESS meet prespecified definition postmenopausal use prespecified acceptable method contraception Hospitalisation COPD exacerbation 6 week prior Visit 1 runin Patients require oxygen therapy chronic hypoxemia ( typically &gt; 15h/day ) Respiratory tract infection within 6 week prior Visit 1 runin period Concomitant pulmonary disease Asthma history ( eosinophils &gt; 400/mm3 ; symptom prior age 40 ) . Includes history childhood asthma History long QTc syndrome QTc interval &gt; 450 m male &gt; 470 ms female Patients clinically significant condition clinically relevant laboratory abnormality History reaction sympathomimetic amine inhale medication Inability use dry powder device perform spirometry Irregular day/night , wake/sleep cycle , e.g . shift worker Certain medication COPD ally condition long act bronchodilator must use prior Visit 1 prespecified minimum washout period Patients unable unwilling complete patient diary Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Chronic obstructive pulmonary disease , indacaterol , salmeterol , placebo control</keyword>
</DOC>